Who Is CAR T-Cell Therapy Right For?

Multiple myeloma experts Dr. Dan Vogl, from the University of Pennsylvania’s Abramson Cancer Center, and Dr. Frits van Rhee, from the University of Arkansas for Medical Sciences Myeloma Center, explain which patients could benefit the most from CAR T-cell therapy and who it is not right for. Watch to find out more about the data clinicians currently have and the ongoing research using this type of immunotherapy to treat myeloma.

This program is sponsored by GSK. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

Key Takeaways

  • People who aren’t good candidates for CAR T-cell therapy are those who've had a lot of prior therapies and therefore don’t have enough T cells to be used in this therapy.
  • There are many CAR T-cell clinical trials going on. Many companies are developing new CAR-T cells that differ from one another, so it will take some time to discover which is most effective.
  • Doctors are studying if CAR T-cell therapy is more effective at the start of treatment when the immune system and cells are healthier. Patients who would benefit from early treatment are those who relapse early after a stem cell transplant and high-risk patients.
This article was originally published March 10, 2020 and most recently updated March 18, 2020.
© 2024 HealthCentral LLC. All rights reserved.

More on Multiple Myeloma